Journal article
Refractory sickle cell leg ulcer: is heparan sulphate a new hope?
International wound journal, Vol.13(1), pp.35-38
02/2016
DOI: 10.1111/iwj.12217
PMCID: PMC7949497
PMID: 24618185
Abstract
Patients with sickle cell disease are known to have recurrent lower extremity ulcers that have a high pain score and are resistant to conventional means of wound therapy. This study reports the successful use of synthetic heparan sulphate (Cacipliq20 (R), OTR3, Paris, France) in the treatment of a sickle cell ulcer that had failed to respond to several other means of treatment. Therapeutic success was assessed by complete wound coverage and vast improvement in pain score. This is the first study to report use of heparan sulphate in sickle cell ulcers.
Details
- Title: Subtitle
- Refractory sickle cell leg ulcer: is heparan sulphate a new hope?
- Creators
- Shady Hayek - American University of Beirut Medical CenterSaad Dibo - American University of Beirut Medical CenterJoe Baroud - American University of Beirut Medical CenterAmir Ibrahim - American University of Beirut Medical CenterDenis Barritault - Laboratoire de Recherche sur la Croissance Cellulaire, la Réparation et la Régénération Tissulaires
- Resource Type
- Journal article
- Publication Details
- International wound journal, Vol.13(1), pp.35-38
- Publisher
- Wiley
- DOI
- 10.1111/iwj.12217
- PMID
- 24618185
- PMCID
- PMC7949497
- ISSN
- 1742-4801
- eISSN
- 1742-481X
- Number of pages
- 4
- Language
- English
- Date published
- 02/2016
- Academic Unit
- Surgery
- Record Identifier
- 9984702716302771
Metrics
5 Record Views